<DOC>
	<DOCNO>NCT01179464</DOCNO>
	<brief_summary>The purpose study investigate effect aminobiphosphonate treatment phenotype function circulate Vgamma9Vdelta2-T cell determine whether effect inhibit simultaneous treatment statin .</brief_summary>
	<brief_title>Effect Aminobiphosphonates Statins Circulating Vgamma9Vdelta2-T Cells</brief_title>
	<detailed_description>A total 40 patient enter study . Half patient receive standard intravenous treatment aminobsiphosphonates , half additionally treat statin . Patients already receive statin treatment continue treatment , patient ask whether willing treated statin maximum 5 week . Consenting patient randomize receive i.v . aminobisphosponates plus minus simvastatin 40 mg daily . Simvastatin start one week prior first administration aminobisphosphonates continue maximum 5 week . In patient 10 ml peripheral blood drawn ( t=0 , t=24 hr , t=1 week , t=3-4 week ( prior 2nd aminobisphosphonate administration ) . In addition , patient request measure temperature thrice daily 2 day follow first aminobisphosponate administration . This , relation occurrence febrile response upon aminobisphosponate administration activation expansion Vy9Vd2-T cell suggest . Peripheral blood mononuclear cell isolated drawn peripheral blood . Using intra- extracellular flowcytometry Vy9Vd2-T cell characterize phenotypically ( APC marker : CD1d , CD40 , CD80 , CD83 , CD86 , HLA-DR ; activation/memory marker : CD25 , CD27 , CD45RA , CD45RO , CCR7 ) functionally ( IFN-γ , TNF-α , granzyme B ) . In addition , frequency CD3+ , CD4+ , CD8+ T cell , NK cell , B cell , iNKT cell , CD4+CD25+ regulatory T cell , circulate dendritic cell assess .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients indication intravenous treatment aminobiphosphonate malignant tumor WHO 0,1,2 performance score WHO 3 , 4 performance score prior current use aminobisphosphonates immunosuppressive medication ( NSAID allow ) chemotherapy and/or radiotherapy 4 week prior start aminobisphosphonate administration renal insufficiency ( creatinine clearance &lt; 30 ml/min ) liver enzyme abnormality : bilirubin &gt; 1.5 time ULN ( upper limit normal ) ASAT ALAT &gt; 2.5 time ULN ( absence liver metastasis ) ASAT ALAT &gt; 5 time ULN ( presence liver metastasis ) concomitant use strong inhibitor CYP3A4 , itraconazole , ketoconazole , erytromycin , clarithromycin , hivprotease inhibitor grapefruit juice contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>